Physician profile
Paul Dekker
NPI 1497850614
$5,817.65
in general payments reported to CMS, 2019-2025
43 companies · $21.29 in 2025
The $21.29 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,765 · 2020: $1,060 · 2021: $585 · 2022: $480 · 2023: $790 · 2024: $117 · 2025: $21.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $928.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $928.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $756.01 | 2019-2024 | |
| Janssen Biotech, INC. | $582.83 | 2019-2023 | Tecvayli, Darzalex |
| Genentech USA, INC. | $548.49 | 2019-2023 | Tecentriq, Lunsumio, Gazyva |
| Incyte Corporation | $349.20 | 2019-2023 | Jakafi, Monjuvi, Pemazyre |
| E.R. Squibb & Sons, L.L.C. | $315.76 | 2019-2022 | |
| Celgene Corporation | $277.49 | 2019-2023 | Reblozyl |
| Pfizer INC. | $263.21 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $262.59 | 2019-2023 | Lynparza, Keytruda, Welireg |
| Seagen INC. | $184.48 | 2019-2023 | Adcetris, Tukysa |
| Pharmacyclics LLC, An Abbvie Company | $172.68 | 2019-2023 | Imbruvica |
| Abbvie INC. | $141.04 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $132.96 | 2019-2020 | |
| Gilead Sciences, INC. | $132.03 | 2019-2023 | Trodelvy |
| Epizyme, INC. | $125.37 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.16 | 2019-2020 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Dekker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.